Please enter your username and password below, if you are not yet a member of Oncology Central remember you can register for free.
Already have an account? Login here
Categories // Events Coverage
We spoke with Dr. Yuman Fong (Chief of Surgery, City of Hope, CA, USA) about his recent work presented at the American Association for Cancer Research (AACR; 27–28 April 2020), titled, ‘A first-in-human phase 1 ascending, multiple dose, safety and tolerance study of Vaxinia (CF33-hNIS), a novel chimeric oncolytic poxvirus, administered intratumorally or intravenously in adult patients with mixed advanced solid tumors (MAST)’. Fong’s research interests over the last 25 years have been designing viruses and cells to be used for anticancer therapy.
It's completely free
Written ByYuman Fong (City of Hope, CA, USA)